Literature DB >> 11830621

Serum bilirubin and early mortality after transjugular intrahepatic portosystemic shunts: results of a multivariate analysis.

Dheeraj K Rajan1, Ziv J Haskal, Timothy W I Clark.   

Abstract

PURPOSE: To examine the prognostic utility of the serum bilirubin level before transjugular intrahepatic portosystemic shunt (TIPS) creation as an independent predictor of 30-day mortality in patients who underwent TIPS creation for treatment of variceal hemorrhage.
MATERIALS AND METHODS: Multiple covariates from a cohort of 220 consecutive patients undergoing TIPS creation were analyzed with use of univariate and multivariate logistic regression. These included pre-TIPS total bilirubin levels, modified Child-Pugh class, APACHE II score, intubation status, etiology of liver disease, and acute versus elective shunting.
RESULTS: The mean pre-TIPS serum total bilirubin level was 3.2 mg/dL (range, 0.4-40.3 mg/dL). The bilirubin level was <3 mg/dL in 102 patients, > or = 3.0 mg/dL in 58, > or = 4.0 mg/dL in 34, and > or = 5.0 mg/dL in 27. Each 1.0-mg/dL increase in total bilirubin was associated with 40% greater odds of 30-day mortality (odds ratio = 1.4; 95% CI = 1.2-1.7). Using each threshold as its own referent, bilirubin levels at or greater than 3.0, 4.0, and 5.0 mg/dL stratified patients into increased odds of early death by 5.7, 9.7, and 19.2 times, respectively (all P <.001). A pre-TIPS APACHE II score of >18 increased the odds of early death by a factor of 5.6 (95% CI = 2.4-8.7); modified Child-Pugh class C (vs classes A and B combined) alone increased the odds by a factor of 8.1 (95% CI = 3.6-18.1). Only one of 20 patients (5%) with a pre-TIPS bilirubin level >6.0 mg/dL survived more than 30 days after TIPS creation. In acutely bleeding patients (n = 122) undergoing TIPS creation, bilirubin levels > or = 3.0, > or = 4.0, and > or = 5.0 mg/dL stratified patients into odds ratios of 4.4, 7.1, and 9.8, respectively, compared with 7.1, 13.2, and 9.2 for patients undergoing elective TIPS creation. Combining endotracheal intubation (n = 72) and bilirubin strata yielded mortality odds of 8.3, 12.5, and 20.8 compared with odds of 2.3, 4.6, and 11.2 in nonintubated patients. Combining alcoholic cirrhosis (n = 129) with bilirubin levels yielded mortality odds of 8.0, 10.6, and 18.0 compared with other etiologies of liver disease (odds ratios = 2.9, 7.3, and 22.7).
CONCLUSION: An elevated pre-TIPS bilirubin level is a powerful independent predictor of 30-day mortality after TIPS creation with a 40% increased risk of death for each 1-mg/dL increase above 3.0 mg/dL. The predictive value of this criterion is increased in patients who undergo TIPS procedures electively. The magnitude of the effect on mortality is similar to that of APACHE II scores and modified Child-Pugh class but is simpler to ascertain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11830621     DOI: 10.1016/s1051-0443(07)61932-0

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  20 in total

1.  Transjugular intrahepatic portosystemic shunt-related complications and practical solutions.

Authors:  Renato Ripamonti; Hector Ferral; Marc Alonzo; Nilesh H Patel
Journal:  Semin Intervent Radiol       Date:  2006-06       Impact factor: 1.513

2.  Liver: Early TIPS in patients with cirrhosis and variceal bleeding.

Authors:  Martin Rössle
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10       Impact factor: 46.802

Review 3.  Transjugular intrahepatic portosystemic shunt: An overview.

Authors:  Harjit K Bhogal; Arun J Sanyal
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-11-09

Review 4.  Emergent Transjugular Intrahepatic Portosystemic Shunt Creation in Acute Variceal Bleeding.

Authors:  Mithil B Pandhi; Andrew J Kuei; Andrew J Lipnik; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2020-03-04       Impact factor: 1.513

Review 5.  Transjugular intrahepatic portosystemic shunt for the management of acute variceal hemorrhage.

Authors:  Romaric Loffroy; Louis Estivalet; Violaine Cherblanc; Sylvain Favelier; Pierre Pottecher; Samia Hamza; Anne Minello; Patrick Hillon; Pierre Thouant; Pierre-Henri Lefevre; Denis Krausé; Jean-Pierre Cercueil
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

Review 6.  Percutaneous Portosystemic Shunts: TIPS and Beyond.

Authors:  Leigh C Casadaban; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2014-09       Impact factor: 1.513

7.  Transjugular intrahepatic portosystemic shunt for severe jaundice in patients with acute Budd-Chiari syndrome.

Authors:  Fu-Liang He; Lei Wang; Hong-Wei Zhao; Zhen-Hua Fan; Meng-Fei Zhao; Shan Dai; Zhen-Dong Yue; Fu-Quan Liu
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

Review 8.  Current use of transjugular intrahepatic portosystemic shunts.

Authors:  Timothy M McCashland
Journal:  Curr Gastroenterol Rep       Date:  2003-02

9.  Predictors of mortality after transjugular portosystemic shunt.

Authors:  Mona Ascha; Sami Abuqayyas; Ibrahim Hanouneh; Laith Alkukhun; Mark Sands; Raed A Dweik; Adriano R Tonelli
Journal:  World J Hepatol       Date:  2016-04-18

10.  Prediction of mortality after emergent transjugular intrahepatic portosystemic shunt placement: use of APACHE II, Child-Pugh and MELD scores in Asian patients with refractory variceal hemorrhage.

Authors:  Wen-Sheng Tzeng; Reng-Hong Wu; Ching-Yih Lin; Jyh-Jou Chen; Ming-Juen Sheu; Lok-Beng Koay; Chuan Lee
Journal:  Korean J Radiol       Date:  2009-08-25       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.